Physician profile
Ashley Lee
NPI 1144730714
$3,250.28
in general payments reported to CMS, 2019-2025
30 companies · $885 in 2025
The $885 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $382 · 2023: $703 · 2024: $823 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.10 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $272.35 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Medtronic, INC. | $206.92 | 2022-2025 | Interstim |
| Alexion Pharmaceuticals, INC. | $201.35 | 2024 | |
| Inspire Medical Systems, INC. | $171.01 | 2023-2025 | Inspire |
| Sk Life Science, INC. | $107.34 | 2024 | Xcopri |
| Corcept Therapeutics | $103.84 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $103.32 | 2021 | |
| Amgen INC. | $103.32 | 2025 | Evenity |
| United Therapeutics Corporation | $102.83 | 2025 | |
| Corium, LLC | $102.58 | 2023 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $102.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $102.58 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $102.58 | 2023 | Dupixent |
| Abbott Laboratories | $100.81 | 2023 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $100.14 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $99.81 | 2024 | |
| Novo Nordisk INC | $96.53 | 2021 | |
| Evoke Pharma, INC. | $94.70 | 2023 | Gimoti |
| Neurelis, INC. | $92.47 | 2024 | Valtoco |
| Sage Therapeutics, LLC | $91.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.26 | 2024 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $88.43 | 2022 | |
| Abiomed | $64.82 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.82 | 2021 | |
| Lucid Diagnostics INC. | $45.91 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $33.53 | 2023 | Givlaari |
| Intercept Pharmaceuticals, INC. | $20.91 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.43 | 2023 | |
| Redhill Biopharma INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.